

HBV Forum 9

12:00 PM	Registration & Lunch	
1:00 PM	Welcome from the Forum	<i>Mitchell Leus, Forum for Collaborative Research</i>
1:05 PM	Introductory Remarks: HBV Forum Co-chairs	<i>Oliver Lenz, Janssen Pharmaceuticals</i>
		<i>Marion Peters, University of California, San Francisco</i>
Session I: Working Group Updates		
Moderators: Veronica Miller, Forum for Collaborative Research & Oliver Lenz, Janssen Pharmaceuticals		
1:10 PM	CAM Nomenclature Working Group	<i>Oliver Lenz, Janssen Pharmaceuticals</i>
1:15 PM	Stopping Finite Treatment Working Group	<i>Marion Peters, University of California, San Francisco</i>
1:30 PM	Patient Advocate Perspective	<i>Maureen Kamischke, Hepatitis B Foundation Su Wang, Center for Asian Health, Saint Barnabas Medical Center</i>
Session II: HDV Co-Infection Working Group		
Moderators: Pietro Lampertico, University of Milan & Robert Gish, Medical Director, Hepatitis B Foundation		
1:40 PM	HDV RNA Assays Writing Group – Paper Outline	<i>Heiner Wedemeyer, Hannover Medical School</i>
2:00 PM	Regulatory Perspective on HDV Diagnostics/Endpoints	<i>Maria Ines Garcia, FDA, Center for Devices and Radiological Health</i>
		<i>Michael Thomson, FDA, Center for Drug Evaluation and Research</i>
2:10 PM	Patient Advocate Perspective	<i>Maureen Kamischke, Hepatitis B Foundation Su Wang, Center for Asian Health, Saint Barnabas Medical Center</i>
2:15 PM	Discussion	<i>Aimee Hodowanec, FDA, Center for Drug Evaluation and Research</i>
2:50 PM	Break	
Session III: Biomarkers		
Moderators: Marc Ghany, NIH, National Institute of Diabetes and Digestive and Kidney Diseases & Debika Battacharya, University of California, Los Angeles		
3:20 PM	Gilead Biomarkers Program	<i>Jeffrey Wallin, Gilead Sciences, Inc</i>
3:30 PM	GSK Biomarkers Program	<i>Dickens Theodore, GlaxoSmithKline</i>
3:40 PM	Biomarkers Project at HBV Forum	<i>Veronica Miller, Forum for Collaborative Research</i>
		<i>Doug Mayers, Antios Therapeutics</i>
3:55 PM	Discussion	
Session IV: Matching the Mechanism of Action to the HBV Subpopulation Working Group		
Moderators: Michael Biermer, Janssen Pharmaceuticals & Jordan Feld, Toronto Centre for Liver Disease		
4:30 PM	Working Group Aims and Goals	<i>Michael Biermer, Janssen Pharmaceuticals</i>
		<i>Jordan Feld, Toronto Centre for Liver Disease</i>
4:45 PM	Drug Development in HBeAg Positive Subpopulations	<i>Patrick Kennedy, Queen Mary University of London</i>
4:55 PM	Drug Development in HBeAg Negative Subpopulations	<i>Pietro Lampertico, University of Milan</i>
	Panel Discussion	<i>Maurizia Brunetto, University Hospital of Pisa</i>
		<i>Harel Dahari, Loyola University Chicago</i>
		<i>Carey Hwang, Vir Biotechnology</i>
		<i>Patrick Kennedy, Queen Mary University of London</i>
		<i>Pietro Lampertico, University of Milan</i>
		<i>Patricia Mendez, Gilead Sciences, Inc</i>
		<i>Dickens Theodore, GlaxoSmithKline</i>
<i>Chloe Thio, Johns Hopkins University</i>		
6:00 PM	Adjourn and HBV Forum Evening Reception	
6:30 PM	HBV Forum, Liver Forum and PSC Forum Evening Reception	